ArticleJCEM case reports2026
Exogenous Insulin Antibody Syndrome and Subsequent Severe Subcutaneous Insulin Resistance Complicating Type 1 Diabetes.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A young girl with type 1 diabetes mellitus (T1D) developed exogenous insulin antibody syndrome (EIAS) characterized by daytime hyperglycemia and ketosis alternating with prolonged severe nocturnal hypoglycemia. EIAS was diagnosed after the exclusion of other causes of hypoglycemia and with confirmation of very high insulin autoantibody levels, high plasma levels of bound insulin, and abnormal insulin clearance. Treatment with different insulin analogues, subcutaneous (SC) insulin pump, immunomodulation using corticosteroids, and intravenous (IV) immunoglobulin were not effective. She responded well to B-lymphocyte depletive therapy (rituximab) with a fall in insulin antibody levels and returned to usual T1D management with a marked improvement in severity of hypoglycemia. One year later she developed hyperglycemia and ketosis and showed no glycemic effect from SC insulin. She became dependent on IV insulin and was diagnosed with severe subcutaneous insulin resistance (SIR). She managed IV insulin at home but developed episodes of sepsis and central line blockage. Many treatment strategies failed, but successful management was finally achieved with the addition of heparin to insulin lispro via SC pump. EIAS and SIR are both extremely rare and, in this case, responded to very different treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.